Kenneth Sha, MD
Pulmonary Disease · Flushing, NYNPI 1821097932
Payments from drug & device makers
Across 1,109 payments — averaging $23.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$4K
- Boehringer Ingelheim$3K
- AstraZeneca$3K
- Mallinckrodt Hospital Products Inc.$3K
- Regeneron Healthcare Solutions, Inc.$2K
- Actelion Pharmaceuticals US, Inc.$1K
- plus $9K from 37 others
What the payments were for
- Food & beverage$25,30798%
- Education$6322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,939 in reported general payments places this provider in the 85th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 144 | $2,038,294 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,614 | $1,083,196 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 965 | $659,699 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 1,274 | $604,763 |
| ActharCorticotropin | 13 | $583,569 |
| AdempasRiociguat | 30 | $397,638 |
| OpsumitMacitentan | 27 | $332,121 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 21 | $317,970 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 546 | $289,860 |
| Breo ElliptaFluticasone/Vilanterol | 621 | $288,965 |
| Spiriva RespimatTiotropium Bromide | 259 | $150,299 |
| Incruse ElliptaUmeclidinium Bromide | 331 | $134,650 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 204 | $101,950 |
| SymbicortBudesonide/Formoterol Fumarate | 364 | $92,437 |
| Fasenra PenBenralizumab | 15 | $88,580 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $3,226 | $2,580,4031,153 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $3,949 | $2,231,0774,086 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $3,113 | $769,1851,362 claims |
| Mallinckrodt Hospital Products Inc.Acthar | $3,109 | $583,56913 claims |
| BayerAdempas | $87 | $397,63830 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $1,415 | $332,12127 claims |
| Insmed, Inc.Arikayce | $1,383 | $317,97021 claims |
| PfizerEliquis | $75 | $56,70373 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $222 | $15,74929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Flushing
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
- Daniel LachantRochester$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.